When was Axelyf founded?

Axelyf was founded in 2022 and raised its 1st funding round 3 years after it was founded.

Where is Axelyf located?

Axelyf is headquartered in Hafnarfjordur, Iceland.

Who is the current CEO of Axelyf?

Orn Almarsson of Axelyf. They have also founded 1 company.

How many employees does Axelyf have?

As of Jul 31, 2026, the latest employee count at Axelyf is 15.

Is Axelyf a funded company?

Axelyf is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jul 25, 2025.

When was the latest funding round of Axelyf?

Axelyf's latest funding was a $***** Seed round on Jul 25, 2025, with participation from 2 investors.

Where does Axelyf rank among its competitors?

Axelyf ranks 196th amongst 417 active competitors, of which 148 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Axelyf?

Axelyf's top competitors include Sana Biotechnology, Viridian Therapeutics and Autolus. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Axelyf - 2026 Company Profile, Team, Funding & Competitors

Axelyf is a seed company based in Hafnarfjordur (Iceland), founded in 2022 by Orn Almarsson and Brynja Einarsdottir. It operates as a Developer of therapeutics for metabolic diseases and inflammatory conditions. Axelyf has raised $4.84M in funding from Brunnur Ventures. The company has 417 active competitors, including 148 funded and 77 that have exited. Its top competitors include companies like Sana Biotechnology, Viridian Therapeutics and Autolus.

Company Details

Developer of therapeutics for metabolic diseases and inflammatory conditions. The company uses prodrugs of natural lipids, lipid nanoparticles and machine learning technology to develop RNA-based vaccines and medicines for metabolic diseases and inflammatory conditions.

Website: www.axelyf.com/
Email ID: *****@axelyf.com

Key Metrics

Founded Year

2022

Location

Hafnarfjordur, Iceland

Stage

Seed

Total Funding

$4.84M in 1 round

Latest Funding Round

Seed, Jul 25, 2025, $*****

Investors

Brunnur Ventures & 1 more

Ranked

196^th among 417 active competitors

Employee Count

15 as on Jul 31, 2026

Similar Companies

Sana Biotechnology & 449 more

View Axelyf's full profile

Axelyf has raised a total funding of $4.84M over 1 round. Its latest funding round was a Seed round on Jul 25, 2025 for $*****. 2 investors participated in its latest round. Axelyf has 2 institutional investors.

Here is the list of recent funding rounds of Axelyf:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 25, 2025	7848098	Seed	7385732	2577444	7619651	9918810

Access funding benchmarks and valuations. Sign up today!

View details of Axelyf's funding rounds and investors

The founders of Axelyf are Orn Almarsson and Brynja Einarsdottir. Orn Almarsson is the CEO of Axelyf.

Here are the details of Axelyf's key team members:

Orn Almarsson: Co-Founder & CEO of Axelyf.
Contact Info: 1 email address
Brynja Einarsdottir: Co-Founder of Axelyf.
Contact Info: 1 email address

View details of Axelyf's Founder profiles and Board Members

Axelyf's employee count trend

Axelyf has 15 employees as of Jul 26. Here is Axelyf's employee count trend over the years:

Uncover Axelyf's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Axelyf include Sana Biotechnology, Viridian Therapeutics and Autolus. Here is the list of Top 10 competitors of Axelyf, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	69/100
2nd	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Longitude Capital, Fairmount Funds Management ... & 2 others	69/100
3rd	Autolus 2015, London (United Kingdom), Public	Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases	$181M	Syncona, 4Bio Capital & 7 others	65/100
4th	Alumis 2003, San Francisco (United States), Public	Developer of therapeutics for the treatment of auto-immune disease	$529M	Foresite Capital, VenBio & 15 others	65/100
5th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	65/100
6th	Retro 2020, Redwood City (United States), Series D	Developer of therapeutics targeting cellular mechanisms to treat aging diseases	$180M	-	64/100
7th	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	64/100
8th	Q32 Bio 2018, Cambridge (United States), Public	Developer of drugs for treating autoimmune disorders	$106M	Atlas Venture, Orbimed & 9 others	63/100
9th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	62/100
10th	VTV Therapeutics 1999, High Point (United States), Public	Developer of small molecules for diabetes, muscle weakness and inflammatory diseases	$124M	SVB, Samsara BioCapital & 12 others	62/100
196th	Axelyf 2022, Hafnarfjordur (Iceland), Seed	Developer of therapeutics for metabolic diseases and inflammatory conditions	$4.84M	Brunnur Ventures, Silfurberg	33/100